

Prokinetic and Antiemetic drugs



Presented by

Dr. Heba Ahmed Hassan

Assistant Professor of clinical pharmacology

Pharmacology Department, Faculty Of Medicine , Muthah
University

Prokinetic drugs

Motility Disorders


An anatomical illustration of the human digestive system, showing the stomach, small intestine, and large intestine. The small intestine is highlighted with a bright red glow, indicating a point of interest or a site of a motility disorder. The rest of the digestive system is rendered in a translucent blue color. The text "Motility Disorders" is overlaid in white, bold font across the upper part of the illustration.

PROKINETIC AGENTS


⦿ Drugs that selectively stimulate gut motor function.


⦿ Motility disorders of the GIT:

- Achalasia of the esophagus
- Drugs that improve gastric emptying may be helpful for gastroparesis and postsurgical gastric emptying delay.
- Agents that stimulate the small intestine may be beneficial for postoperative ileus or chronic intestinal pseudo-obstruction.
- Agents that enhance colonic transit may be useful in treatment of constipation




ANTIEMETICS and PROKINETICS







Dopamine (D₂) antagonists:
Metoclopramide Domperidone Sulpiride.



Serotonin receptor modulators:
Tegaserod Cisapride Prucalopride



Cholinomimetic agents:
Bethanechol stimulates M₃ (now seldom used). Neostigmine I.V. 2 mg. drug of choice (Acute Colonic Pseudo-obstruction).



Directly stimulate motilin receptors
Macrolides

METOCLOPRAMIDE (PRIMPERAN)



□ Pharmacokinetic:


- Rapidly absorbed.
- Half life 4-6 hrs.
- Distributed rapidly to most tissues (**bl. brain barrier**, placenta, milk).
- Hepatic metabolism (sulfation & glucuronidation).
- Excreted in urine.

□ Mechanism of action:

- ***D₂ receptor antagonist.***
- Promotes release of Ach from myenteric plexus (***5-HT₄ agonist***)
- ***5-HT₃ antagonists.***

□ Pharmacological effects:

- **1. C.N.S.:** D₂-blocker.
 - Antiemetic. (CTZ)
 - Hyperprolactinemia. Extrapyrasidal symptoms. (basal ganglia)



2.G.I.T.: ↑ esophageal peristaltic amplitude, ↑ LES, and enhances gastric emptying (upper digestive tract) but **has no effect upon small intestine or colonic motility.**

➔ **Uses:**

1. **Antiemetic** (potent antiemetic).

2. **Prokinetic action:**

A. GERD (Gastroesophageal reflux disease) (rarely used).

B. Gastric hypomotility & postoperative ileus.



C. To facilitate intubation procedure (nasogastric feeding tube) and radiological examination of gut.

D. To empty the stomach before emergency surgery

E. Hiccough.

⇒ Side effects:

1. **Restlessness**, drowsiness, insomnia, anxiety & agitation (10-20%, especially the elderly).
2. **Extrapyramidal effects** (dystonia, akathisia, parkinsonian features).
 - 25% in high doses & 5% in long term therapy.
 - Tardive dyskinesia, sometimes irreversible (in long term therapy).
 - Long term use should be avoided unless absolutely necessary, especially in the **elderly**.
3. Stimulates **prolactin release** → Galactorrhea, gynecomastia, impotence & menstrual disorders.



➔ **Doses:** 10-20 mg orally or I.V. every 6hrs.

➔ **Drug interactions:**

1. Short transit time in the stomach → ↑ absorption of paracetamol & ↓ absorption of digoxin.
2. Potentiates action of neuroleptics (Antipsychotics)
3. Antagonizes action of antiparkinsonian drugs.

DOMPERIDONE (MOTILIUM)

⊙ ➔ **Pharmacokinetics:**

- Rapidly absorbed. ■ Half-life 7-8 hrs.
- Excreted in feces.

⊙ ➔ **Mechanism of action:** D₂-blocker.

⊙ ➔ **Pharmacological effects:** As Metoclopramide.

⊙ **Rarely crosses bl. brain barrier** (rare extra-pyramidal reactions).

⊙ Hyperprolactinaemia.



CISAPRIDE AND PRUCALOPRIDE



- ⊙ ➔ **Mechanism of action:** (5HT₄ agonist) → Release of myenteric Ach.
- ⊙ ➔ **Pharmacological effect:** Acts on both upper and lower gut.
- ⊙ ➔ **Uses:**
 - Prokinetic.
 - Chronic idiopathic constipation and colonic hypomotility.
- ⊙ ➔ **Side effects:**
 - Diarrhea.
 - **Arrhythmia** (due to inhibition of cardiac hERG K⁺ channels, which results in QT prolongation in some patients).

N.B:

Prucalopride: Does NOT significantly block hERG K⁺ channels, Very low risk of QT prolongation.

MACROLIDES

- ◉ ➔ Directly stimulate **motilin** receptors on G.I.T. smooth muscle and promote the onset of a migrating motor complex.
- ◉ ➔ **Uses:**
 - 1. IV **erythromycin** in gastroparesis, however tolerance rapidly develops.
 - 2. Acute upper GIT hemorrhage to promote gastric emptying of blood prior to endoscopy.

(LUBIPROSTONE)



- ◉ Acts by stimulating **chloride channel** opening in the intestine → ↑ liquid secretion into the intestine & shortens intestinal transit time.
- ◉ Used in **chronic constipation**
- ◉ **USED IN IBS WITH CONSTIPATION**

LINACLOTIDE

- ❑ **Activates guanylate cyclase-C (GC-C) receptors** on intestinal epithelial cells, ↑ intracellular cGMP → secretion of Cl^- and HCO_3^- into intestinal lumen with **Reducing Visceral pain sensation**
- ❑ **Uses:** 1. Chronic Idiopathic Constipation (CIC)
- ❑ 2. Irritable Bowel Syndrome with Constipation (IBS-C), **Especially useful because it Relieves both constipation + abdominal pain**

Antiemetics







FIGURE 62-6 Neurologic pathways involved in pathogenesis of nausea and vomiting (see text). (Modified and reproduced, with permission, from Krakauer EL et al: Case records of the Massachusetts General Hospital. N Engl J Med 2005;352:817.)

1. Anti-histaminics (H1) antagonists
2. Muscarinic-receptor (M1) antagonists
3. Neurokinin (NK1) receptors antagonists
4. DOPAMINERGIC (D2) ANTAGONIST
5. Serotonin (5HT₃) antagonists
6. Cannabinoids
7. CORTICOSTEROIDES
8. Benzodiazepines
9. VOMITING WITH PREGNANCY

1- SEROTONIN (5HT₃) ANTAGONISTS

Ondansetron



- Ondansetron, Granisetron, Dolasetron, Palonosetron

Pharmacokinetics :

- **Ondansetron, granisetron & dolasetron** have a serum half-life of 4-9 hours and may be administered once daily by oral or IV routes.
- **Palonosetron (IV)** has greater affinity for 5-HT₃ receptors & long t_{1/2} (40hrs).
- All four drugs undergo **extensive hepatic metabolism**.
- They are eliminated by **renal and hepatic excretion**. However, **dose reduction is not required** in geriatric or renal insufficiency.
- **Dose reduction may be required** with **ondansetron** in patients with renal insufficiency.

- **Mechanism of action:** Potent antiemetic.

- **Central 5-HT₃ receptors blockade.**
- **Peripheral 5-HT₃ receptors blockade** on extrinsic intestinal vagal and spinal afferent nerves → inhibit unpleasant visceral afferent sensation including nausea, bloating and pain.



Clinical uses:

1- Chemotherapy-induced nausea & vomiting:

- **Primary agents** for the prevention of **acute** nausea and vomiting < 24 hrs???
- When used alone, these drugs have little or **no efficacy for the prevention of delayed nausea and vomiting** (occurring > 24 hrs. after chemotherapy)???
- These drugs are most effective when given as a **single dose by I.V. injection 30-60 minutes** prior to administration of chemotherapy in the following doses: ondansetron (8mg), granisetron (1mg), dolasetron (100 mg) or palonosetron (0.25 mg).
- A single oral dose given 1 hr. before chemotherapy may be equally effective in the following regimens: ondansetron (8 mg twice daily or 24 mg once), granisetron (2mg), dolasetron (100mg).
- Although effective as single agents, their efficacy is **enhanced by combination therapy** with a corticosteroid (**dexamethasone**) and **Neurokinin (NK1) receptors antagonists (delayed nausea and vomiting)**.

2. Postoperative & postradiation nausea & vomiting

◎ Side effects: Well-tolerated agents

1. Headache, dizziness & constipation.

2. All four agents cause a small but statistically significant **prolongation of the QT interval** (block cardiac potassium channels, hERG (IKr) K⁺ channels), but this is **most pronounced with dolasetron** (Dolasetron should not be administered to patients with prolonged QT or with other medication that may prolong the QT interval).

2- DOPAMINERGIC (D₂) ANTAGONISTS

a. **Phenothiazines**

b. **metoclopramide (Primperan).**

c. **Domperidone (Motilium).**

d. **Sulpiride (Dogmatil).**

Mechanism of action: D₂-blocker; centrally in CTZ & Peripherally in stomach.

Uses: Vomiting due to uremia, radiation sickness, acute viral gastroenteritis, cancer chemotherapy, narcotic analgesics & estrogens

3- MUSCARINIC-RECEPTOR ANTAGONISTS (HYOSCINE)

- ⊙ Depresses vomiting center.
- ⊙ Its anti-emetic action peaks 1-2 hrs after ingestion.
- ⊙ **Duration:** 4-6 hrs.
- ⊙ **Uses:** Prophylaxis against motion sickness (short duration of action → used in air sickness).
- ⊙ **Side effects:** Blurred vision and dry mouth.
- ⊙ **Doses:** 0.6 mg oral or parenteral 30 min before journey.
Transdermal patch can be used.

4- ANTI-HISTAMINICS (H1) ANTAGONISTS)

A- Ethanolamine

Marked sedation & Anti-muscarinic effects.

- Diphenhydramine.
- Dimenhydrinate (Dramamine).
- Doxylamine (in Bendectin).

B- Phenothiazines

Marked sedation & Anti-muscarinic effects.

- promethazine

C- Piperazine

Slight sedation.

- Cyclizine (Maxine).
- Meclizine (Bonamine).
- Cinnarizine.



Peak anti-emetic effect: 4 hrs.

Duration: 24 hrs.

Uses: weak antiemetic.

1. Prophylaxis against **motion sickness** (Meclizine).

➤ Long duration of action → used in **sea sickness**

2. Diphenhydramine is used in conjunction with other anti-emetics for treatment of vomiting due to chemotherapy

5- CANNABINOIDS

- ◎ ■ **Nabilone** ■ **Dronabinol**
- ◎ The major psychoactive chemical in marijuana.
- ◎ **Side effects:** euphoria, dysphoria, sedation, hallucination, dry mouth and increased appetite.

6- CORTICOSTEROIDS

Dexamethazone ■ **Methylprednisolone**

- ◎ These agents **enhance the efficacy of 5-HT₃ receptor antagonists** for prevention of acute & delayed nausea and vomiting in patients receiving moderately to highly emetogenic chemotherapy.
- ◎ **Dose:** **Dexamethasone** (8-20 mg I.V.) before chemotherapy, followed by 8mg/d orally for 2-4 days.

7- BENZODIAZEPINES

- ■ Lorazepam ■ Diazepam
- Used prior to the initiation of chemotherapy to **reduce anticipatory vomiting** or vomiting **caused by anxiety**.

8- NEUROKININ (NK1) RECEPTORS ANTAGONISTS

- Aprepitant (oral) ■ Fosaprepitant (I.V.)
- Central blockade NK₁ receptor in CTZ.
- Pharmacokinetics:
- Bioavailability 65% ■ Half-life: 12 hrs.
- Metabolized by the liver, primarily by the CYP3A4

Clinical uses:

- Combined with 5-HT₃ antagonists & corticosteroids for the prevention of acute & delayed nausea and vomiting from highly emetogenic chemotherapeutic regimen.

Side effects: Fatigue, dizziness & diarrhea.

Drug interactions:

- Inhibit the metabolism of other drugs metabolized by CYP3A4 (e.g. ketoconazole, ciprofloxacin, clarithromycin, verapamil, quinidine).

9. Vomiting of pregnancy

- Treated with vitamin B6 (Pyridoxine) + Doxylamine. 1st line (safe)
- Ondansetron → effective but cautious use
- Steroids → only severe cases
- Supportive treatment

